Mast cell sarcoma

Revision as of 17:16, 6 September 2024 by Bailey.Glen (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Haematolymphoid Tumours (WHO Classification, 5th ed.)

editContent Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Mast Cell Sarcoma.

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

Jordan Lowery, MD and Thuy Phung, MD, PhD

Department of Pathology, University of South Alabama, Mobile, AL

WHO Classification of Disease

Structure Disease
Book Haematolymphoid Tumours (5th ed.)
Category Myeloid proliferations and neoplasms
Family Mastocytosis
Type N/A
Subtype(s) Mast cell sarcoma

Definition / Description of Disease

Localized, solid tumor composed of highly atypical mast cells with a destructive growth pattern and metastatic potential.[1][2]

Synonyms / Terminology

Malignant Mast Cell Tumor

Malignant Mastocytoma

Epidemiology / Prevalence

Mast cell sarcoma is a rare entity with no clear gender predilection.[2][1] Cases have been reported in a wide range of ages from infancy to 77 years of age.[3][4] Most cases seem to arise de novo, but two cases have developed in patients with a history of cutaneous mastocytosis.[1]

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table. Do not delete table.)

Signs and Symptoms EXAMPLE: Asymptomatic (incidental finding on complete blood counts)

EXAMPLE: B-symptoms (weight loss, fever, night sweats)

EXAMPLE: Fatigue

EXAMPLE: Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE: Cytopenias

EXAMPLE: Lymphocytosis (low level)


editv4:Clinical Features
The content below was from the old template. Please incorporate above.

The presentation is variable. The disease is initially localized, followed by distant spread and a terminal phase resembling mast cell leukemia.[2] Progression usually occurs quickly and prognosis is poor. Mast cell sarcoma often results in death within a few months.[1] Treatment includes imatinib, a tyrosine kinase inhibitor that blocks PDGF-R (platelet-derived growth factor receptor) and the tyrosine kinase proteins encoded by abl (the Abelson proto-oncogene) and KIT, or other tyrosine kinase inhibitors.[3] Surgical debulking, radiation and chemotherapy are the usual first-line therapies.[5][6] Hematopoietic stem cell transplantation represents a potential curative treatment, but evidence of its efficacy is lacking.[1]

Sites of Involvement

Bone, gastrointestinal tract, lymph nodes, skin, spleen, liver, oropharyngeal tract, meninges, uterus, testicles and eyes.[1]

Morphologic Features

Mast cell sarcoma exhibits a solid growth pattern.  Microscopically, this tumor is poorly differentiated and heterogeneous. Mast cell sarcoma cells are usually medium to very large, with pleomorphic or epithelioid cellular features and oval or bilobed nuclei. Multinucleated giant cells may be identified.[1]  Histologic features may even vary between sites within the same patient. The typical features of systemic mastocytosis, including multifocal dense infiltrates of greater than 14 mast cells, are rarely seen in mast cell sarcoma.[2]

Immunophenotype

Finding Marker
Positive Tryptase, stem cell factor receptor KIT (CD117), common leukocyte antigen (CD45), macrosialin (CD68R), amiopeptidase N (CD13), C5a receptor (CD88), GM-CSF receptor alpha chain (CD116)[7]
Negative CD1a, CD2, CD3, CD5, CD14, CD15, CD19, CD20, CD34, CD114[7]

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: t(9;22)(q34;q11.2) EXAMPLE: 3'ABL1 / 5'BCR EXAMPLE: der(22) EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add reference)

Yes No Yes EXAMPLE:

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).


editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)

The KIT Asp816Val mutation confers resistance to imatinib.[8] Other reported mutations in the KIT gene, including Asn822Lys and Leu779Phe, may also confer resistance to tyrosine kinase inhibitors, as suggested by patient outcomes and proximity to the tyrosine kinase domain.[9][10]

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

7

EXAMPLE: Loss EXAMPLE:

chr7:1- 159,335,973 [hg38]

EXAMPLE:

chr7

Yes Yes No EXAMPLE:

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

EXAMPLE:

8

EXAMPLE: Gain EXAMPLE:

chr8:1-145,138,636 [hg38]

EXAMPLE:

chr8

No No No EXAMPLE:

Common recurrent secondary finding for t(8;21) (add reference).

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations

EXAMPLE: TSG EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).


Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.
Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
KIT exon 17 c.2447A>T, p.Asp816Val Proto-oncogene GOF 3 cases[1]
KIT exon 17 c.2395C>T, p.Leu779Phe Proto-oncogene GOF 1 case[10]
KIT exon 8 c.1255del  

p.Asp419Tfs*4

Proto-oncogene GOF 1 case[11]
KIT exon 17 c.2466T>A

p.Asn822Lys   

Proto-oncogene GOF 1 case[9]
KIT exon 11 c.1679T>G

p.Val560Gly

Proto-oncogene GOF 1 case[12]

Epigenomic Alterations

Put your text here

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table. Do not delete table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the old template. Please incorporate above.

The KIT proto-oncogene encodes the KIT (CD117) tyrosine kinase protein receptor. KIT is found on hematopoietic progenitor cells, mast cells, germ cells, melanocytes, and interstitial cells of Cajal. Most hematopoietic stem cells loose KIT expression during maturation. However, mature mast cells continue to express KIT.  Stem Cell Factor protein is the ligand which binds to KIT protein, leading to dimerization and activation of signaling cascades involved in a wide variety of cellular roles, including regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function. In addition to mast cell disorders, mutations in this gene are found in gastrointestinal stromal tumors and acute myeloid leukemia.[13][14]

Genetic Diagnostic Testing Methods

Although non-sequencing methods have been used, sequencing of the entire KIT gene by Sanger sequencing, pyrosequencing or next generation sequencing (NGS) is recommended to identify unknown KIT mutations.[1]

Familial Forms

Most reported cases are sporadic.[1] However, one reported case of mast cell sarcoma arose in a background of familial indolent mastocytosis with urticaria pigmentosa. No KIT mutations were identified in this case.[12]

Additional Information

Put your text here

Links

KIT

References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 J, Monnier; et al. (2016). "Mast cell sarcoma: new cases and literature review". doi:10.18632/oncotarget.11812. PMC 5323235. PMID 27602777.CS1 maint: PMC format (link)
  2. 2.0 2.1 2.2 2.3 Arber DA, et al., (2017). Mast cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p. 62-69.
  3. 3.0 3.1 Rj, Ryan; et al. (2013). "Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications". PMID 23196796.
  4. Ma, Bautista-Quach; et al. (2013). "Mast cell sarcoma in an infant: a case report and review of the literature". PMID 23211696.
  5. P, Valent; et al. (2017). "Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts". doi:10.1182/blood-2016-09-731893. PMC 5356454. PMID 28031180.CS1 maint: PMC format (link)
  6. Cr, Weiler; et al. (2014). "Mast cell sarcoma: clinical management". PMID 24745684.
  7. 7.0 7.1 A, Chott; et al. (2003). "Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma". PMID 12826896.
  8. C, Akin; et al. (2003). "Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit". PMID 12901973.
  9. 9.0 9.1 A, Bugalia; et al. (2011). "Mast cell sarcoma of the small intestine: a case report". PMID 21778298.
  10. 10.0 10.1 Ys, Kim; et al. (2013). "Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm". PMID 23388130.
  11. Rj, Ryan; et al. (2013). "Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications". PMID 23196796.
  12. 12.0 12.1 S, Georgin-Lavialle; et al. (2013). "Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature". PMID 23129735.
  13. "KIT - Mast/stem cell growth factor receptor Kit precursor - Homo sapiens (Human) - KIT gene & protein".
  14. L, Falchi; et al. (2018). "Kit Mutations: New Insights and Diagnostic Value". PMID 30007460.

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome. *Citation of this Page: “Mast cell sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 09/6/2024, https://ccga.io/index.php/HAEM5:Mast_cell_sarcoma.